CD166 expression in dentigerous cyst, keratocystic odontogenic tumor and ameloblastoma by Andisheh Tadbir, Azadeh & Gorgizadeh, Ali
J Clin Exp Dent-AHEAD OF PRINT                                                                                                                                                                   CD166 expression in odontogenic lesions
E1
Journal section: Oral Medicine and Pathology                            
Publication Types: Research
CD166 expression in dentigerous cyst, keratocystic 
odontogenic tumor and ameloblastoma
Azadeh Andisheh-Tadbir 1, Ali Gorgizadeh 2
1 Associate Professor, Prevention of Oral and Dental Disease Research Center, Department of Oral and Maxillofacial Pathology, 
School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran
2 Undergraduate Student, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran
Correspondence:
Prevention of Oral and Dental Disease Research Center
Department of Oral and Maxillofacial Pathology
School of Dentistry






Background: CD166 is a glycoprotein of an immunoglobulin super family of adhesion molecules that has been 
associated with aggressive characteristics and high recurrence rate of tumors. Different odontogenic lesions ex-
hibit considerable histological variation and different clinical behavior. In an attempt to clarify the mechanisms 
underlying this different behavior, the present study investigates the immunohistochemical expression of CD166 
in these lesions.
Material and Methods: In this study 69 formalin-fixed, paraffin embedded tissue blocks of odontogenic lesion 
consist of 15 unicystic ameloblastoma (UA), 17 solid ameloblastoma (SA), 18 keratocystic odontogenic tumors 
(KCOT), and 19 dentigerous cysts (DC) were reviewed by immunohistochemistry for CD166 staining.
Results: In this study, CD166 immune staining was evident in all specimen groups except dentigerous cyst. In posi-
tive cases, protein localization was cytoplasmic and/or membranous. CD166 expression was seen in76.5% (13) of 
SA, 73.5% (11) of UA, and 66.7% (12) of KCOTs. Statistical analysis showed that CD166 expression levels were 
significantly higher in ameloblastoma (SA and UA) and KCOTs than dentigerous cyst (P<0.001), but there was no 
statistically significant difference between CD166 expression in the other groups (P>0.05).
Conclusions: This data demonstrates that overexpression of CD166 may have a role in the pathogenesis of amelo-
blastoma and KCOT.
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Introduction
Cell junctions connect epithelial cells to one another 
and consist of various proteins, generically called adhe-
sion molecules, which are keys to the regulation of cell 
growth and differentiation (1). 
Adhesion molecules are involved in tumor cell-tumor 
cell adhesion, tumor cell-endothelial cell adhesion, and 
tumor cell-matrix adhesion, all of which are necessary 
for primary tumor formation or metastasis (2). 
A variety of molecules that regulate cell adhesion have 
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been identified and investigated.Adhesion molecules are 
divided into five major groups: immunoglobulins, cad-
herins, selectins, integrins and mucins (2). 
Activated leukocyte cell adhesion molecule, or CD166, 
is a glycoprotein of an immunoglobulin superfamily 
of adhesion molecules (IgCAMs). IgCAMs are mostly 
transmembrane proteins that can function as cell ad-
hesion receptors and transduce signals to intracellular 
signaling pathways (3). The CD166 gene is located on 
chromosome 3 and is composed of 16 exons with a size 
of over 200 Kb (4). 
CD166 is involved in the development of different 
tissues during embryogenesis and functions in adults 
through homotypic and heterotypic interactions between 
cells (4-6). The expression of CD166 has been discove-
red in a subgroup of cells which have a role in dynamic 
growth and migration. It has, however, been discovered 
in cancer stem cells as well (6). 
Altered CD166 expression has also been associated with 
differentiation and progression in prostate (7,8), colo-
rectal (9), and breast cancers (10). 
CD166 expression reflects aggressive characteristics 
and can be associated with high recurrence rate of tu-
mors (9,11).
Different odontogenic lesions arise from the element of 
the tooth-forming apparatus, and its derivatives exhibit 
considerable histological variation and different clinical 
behavior (12,13). 
Dentigerous cyst is the most common developmental 
odontogenic cyst with an indolent behavior and a low 
recurrence rate (14). 
Keratocystic odontogenic tumor (KCOT) has recently 
been recommended to describe the lesion previously na-
med odontogenic keratocyst (15) KCOT is a developmen-
tal cyst which is locally aggressive and rapidly prolifera-
ting and shows a high recurrence rate after removal (16). 
Since radical procedures are suggested for KCOT in con-
trast to dentigerous cyst, the histological investigation of 
this entity has been the focus of many studies (17). 
Ameloblastoma is a benign odontogenic tumor with an 
aggressive behavior and a marked invasive potential that 
leads to multiple recurrences after enucleating and cu-
rettage (18). 
Previous studies disclose the role of different adhesion 
molecules in the pathogenesis and aggressive behavior 
of odontogenic lesions (19,20).
In view of the distinct clinical behavior of KCOT, den-
tigerous cyst, and ameloblastoma, the objective of the 
present study was to investigate the immunohistochemi-
cal expression of CD166 in these lesions. 
Material and Methods
In this study 69 formalin-fixed, paraffin embedded tis-
sue blocks of odontogenic lesion consist of 15 unicystic 
ameloblastoma (UA), 17 solid ameloblastoma (SA), 18 
keratocystic odontogenic tumors (KCOT), and 19 den-
tigerous cysts (DC) were reviewed by immunohistoche-
mistry for CD166 staining.
This study was approved by the Ethics Committee of the 
Shiraz University of Medical Sciences.
H & E slides of available blocks were reviewed, and then 
cases with definite diagnosis and adequate tissue were 
selected for immunohistochemical staining (IHC). Cases 
with severe inflammation were excluded from the study.
IHC staining was performed using the Envision Labe-
led Peroxides System (DAKO, Carpentaria, CA, USA). 
All samples were fixed in 10% buffered formalin and 
embedded in paraffin. Sections of 4μ thickness were 
prepared and deparaffinized in histology grade Xylene, 
rehydrated in graded alcohol, and washed with distilled 
water. Antigen retrieval was performed using DAKO 
cytomation target retrieval solution with PH = 9 for 20 
minutes. Internal peroxidase activity was inhibited by 
3% H2O2.
Tissue sections were incubated for 30 minutes with the 
anti-CD166 antibody (clone: MOG/07, 1:450; Novocas-
tra, UK) at 1/100. Normal samples were stained with the 
same amount of antibody used for staining tumor tissues. 
Omission of primary antibody was employed as the ne-
gative control, while oral squamous cell carcinoma was 
used as the positive control.
Brown staining of the cell membrane, cytoplasm or both 
was considered as positive. The immunopositive stai-
ning was evaluated in 5 randomly-selected areas of the 
tissue in the basal and parabasal layers of cystic lesions 
and peripheral cells of ameloblastic nests (magnification 
was 400×), and the percentage of positive tumor cells 
was calculated.
A lesion was designated as overall CD166 positive if 
greater than 10 % of cells exhibited immunoreactivity.
Chi squareand Fisher’s exact tests were used to compare re-
sults. A p value less than 0.05 was considered significant.
Results
In this study, CD166 immune staining was evident in all 
specimen groups except dentigerous cyst (Fig. 1). In po-
sitive cases, protein localization was cytoplasmic and/or 
membranous. CD166 expression was seen in 76.5% (13) 
of SA, 73.5% (11) of UA, and 66.7% (12) of KCOTs. 
Statistical analysis showed that CD166 expression levels 
were significantly higher in ameloblastoma (SA and UA) 
and KCOTs than dentigerous cyst (P<0.001), but there 
was no statistically significant difference between CD166 
expression in the other groups (P>0.05), (Table 1).
Expression of CD166 in follicular and plexiform SAs 
was the same. CD166 positivity was observed on the 
cytoplasm and/or cell membrane of peripheral columnar 
cells and was negative in central stellate reticulum-like 
cells. Expression of the molecule was lost in the kerati-
nized areas of acanthomatous SAs (Figs. 2,3).
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Fig. 1. Negative CD166 expression in  dentigerous cyst (×400).
Fig. 2. Cytoplasmic/membranus CD166 expression in  ameloblast 
like cell in solid ameloblastoma (×200).
Fig. 3. Cytoplasmic/membranus CD166 expression in  plexiform 
ameloblastoma (×200).
Fig. 4. Cytoplasmic/membranus CD166 expression in  unicystic 
ameloblastoma (×200).
Fig. 5. Cytoplasmic/membranus CD166 expression in  odontogenic 
keratocyst (×400).





Solid ameloblastoma 13 (76.5) 4 (23.5)
Unicystic ameloblastoma 11 (73.5) 4 (26.5)
Odontogenic keratocyst
Dentigerous cyst
12 (66.7) 6 (33.3)
0 19 (100) 
Table 1. CD166 expression in different groups of lesion.
The UAs showed a reaction in the basal layer of the cys-
tic lining, but no reaction in the upper layers (Fig. 4).
Expression of CD166 in KCOTs was positive in the cell 
membrane and/or cytoplasm of most of the cells in the 
basal and suprabasal layers, and all layers of epithelial 
budding and daughter cysts (Fig. 5).
Discussion
The invasion, which means the penetration of tumor cells 
into the adjacent environment, is not specific to cancer; 
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it is also found in embryogenesis, healthy organs, and in 
many non-cancerous diseases (21). 
The process of invasion is exceedingly complex, and the 
genetic and biochemical determinants are still unclear 
(22). Recent studies have found genetic and molecular 
alterations in epithelial odontogenic tumors; however, 
details of the mechanism of oncogenesis, cytodifferen-
tiation, and tumor progression remain unknown (23). 
Recent studies have reported that the expression of 
CD166 markers in tumors indicates the aggressive be-
havior of the malignancies in vitro (5,24). The present 
study is the first to have demonstrated the expression of 
CD166 in odontogenic lesions. 
In the present study, CD166 immunoreactivity was hig-
her in ameloblastomas and KCOTs than in DCs. This 
result indicates that CD166 may play a role in the patho-
genesis of ameloblastomas and KCOTs but not in DC. 
The difference in CD166 expression observed in the pre-
sent study might explain the variable behavior of these 
lesions, the highly aggressive and invasive behavior of 
ameloblastomas and KCOTs, and it supports the concept 
that KCOT has a neoplastic potential. 
There was no difference in CD166 expression with res-
pect to unicystic and solid ameloblastoma. It is possible 
that the differences in the clinical behavior of both tu-
mors are determined by other factors than those directly 
associated with the expression of this molecule. 
Two different cell types are observed in all subtypes of 
ameloblastoma: peripheral columnar or ameloblast-like 
cells and central stellate reticulum-like cells (25). Peri-
pheral cells are always located at the invasive front, but 
show no cellular differentiation. By contrast, in many 
cases morphological differentiation was observed in 
central stellate reticulum-like cells (25). 
The present experiment found that positive CD166 im-
munohistochemical reactivity was prominent on the pe-
ripheral columnar cells and absent on the stellate reticu-
lum-like central cells. This result supports the thesis that 
these cells are located at the invasive front, and overex-
pression of CD166 at these cells may promote invasion. 
However, this particular localization of CD166 expres-
sion close to the stroma might emphasize other role of 
CD166 such as cancer stem cell or raise the question of 
whether factors secreted from stromal cells might induce 
CD166 expression. 
A previous study demonstrated that CD166 is a TGF-B 
responsive marker (26). This finding supports the possi-
bility that stromal growth factors may enhance CD166 
expression and contribute to regulation of the invasion 
of ameloblastoma. 
Kaur et al. demonstrated that loss of membrane E-cad-
herin correlated significantly with overall CD166 immu-
nopositivity in hyperplasia of the oral cavity (27). 
Gonzalez-Alva et al. showed that expression of E-cad-
herin decreased in areas of cell-cell contact of the peri-
pheral cells in AMs and retained E-cadherin in the cen-
tral areas of tumor cells (28) and Hakim et al. found that 
E-cadherin staining decreased in KCOTs compared with 
dentigerous cyst (15). To clarify the correlation of these 
two proteins in the odontogenic lesions future studies 
are recommended.
Different cell behaviors are involved in the formation of 
epithelial budding and daughter cyst compared with cyst 
formation. Proliferation of basal cells with the accumu-
lationof cyst contents lead to the wall pushing outward 
and cyst formation. In contrast, invasive protrusion of 
KCOT nests into the adjacent stromal tissue results in 
epithelial islands and daughter cyst formation, which is 
reminiscent of the early stages of tooth germ formation 
(29). 
Shimeda et al. proposed that these histological features 
may represent the invasive potential of KCOT (29). 
In the present study, positive immunoreactivity for 
CD166 was also found in all layers of daughter cyst and 
epithelial budding, which supports the hypothesis of 
Shimeda et al. (29) and the invasive potential of KCOT. 
The mechanism by which CD166 expression contributes 
to tumor progression is currently unclear (30). However, 
Lunter et al. recently found that the proper function of 
the matrix metalloproteinase-2 (MMP-2) was dependent 
on CD166 expression and its function (31). 
This finding suggests that CD166 has a signaling role 
in proteolysis, and CD166 overexpression can enhance 
MMP-2 activity and the breakdown of the extracellular 
matrix, thus resulting in increased tumor invasiveness 
and progression (31). 
Khalifa et al. found that overexpression of the MMP-2 
protein may be one of the factors related to the growth 
and progression of KCOT and ameloblastoma, and it 
may enhance the recurrence of KCOT and invasion of 
ameloblastoma (32).
Because of the unknown biological role of CD166, futu-
re in-vitro studies should focus on the physiological and 
pathological molecular mechanisms and interactions of 
these molecules. 
In conclusion, in this study overexpression of CD166 
was seen in ameloblastoma and KCOT which might be 
related to the aggressive behavior and high recurrence 
rate of these tumors but for supporting this hypothesis 
future studies are recommended.
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